360° SearchNetwork Hot Spots Trends Time Series

Iluvien

Type: Product

Name: Iluvien

First reported May 21 2013 - Updated May 21 2013 - 1 reports

pSivida announces availability of diabetic macular edema drug in Germany

pSivida Corp., a developer of drug delivery products for treatment of back-of-the-eye diseases, has announced the commercial availability of ILUVIEN, a sustained release pharmaceutical product for the treatment of chronic diabetic macular edema in Germany. ... [Published Individual.com - May 21 2013]

Entities: PSIVIDA CORP, Iluvien, Diabetic Macular Edema

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Alimera Sciences announces availability of DME drug in Germany

Alimera Sciences, Inc., a biopharmaceutical company, has announced the commercial availability of ILUVIEN, the sustained release pharmaceutical product for the treatment of chronic diabetic macular edema, or DME, in Germany. ILUVIEN (190 micrograms intravitreal ... [Published Individual.com - May 20 2013]

Entities: Diabetic Macular Edema, Iluvien, Alimera Sciences Inc

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Ophthalmology Innovators: Will InSite Follow Recent Successes?

In advance of the Second Annual Ophthalmology Innovation Summit, Dr. William Link, Managing Director of the $500M healthcare investment firm Versant Ventures, emphasized the factors underlying continued growth of the ophthalmology industry with the International ... [Published Seeking Alpha - May 16 2013]

Entities: Iridex Corporation, Ophthalmology, Azasite

First reported May 14 2013 - Updated May 14 2013 - 2 reports

pSivida: New ILUVIEN PDUFA Date October 17 [Professional Services Close - Up]

pSivida Corp., a developer of sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced that the U.S. Food and Drug Administration (FDA) acknowledged receipt of the resubmission of the New Drug Application (NDA) for ... [Published Pharmacy Choice - May 14 2013]

Entities: Iluvien, Diabetic Macular Edema, PSIVIDA CORP, Prescription Drug User Fee Act

First reported May 09 2013 - Updated May 10 2013 - 4 reports

Alimera Sciences Inc

Alimera Sciences Reports First Quarter 2013 Financial Results

/PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the first ... [Published Bio-Medicine - May 10 2013]

Entities: Iluvien, Alimera Sciences Inc, Diabetic Macular Edema

First reported May 08 2013 - Updated May 09 2013 - 5 reports

SVB Provides Alimera Sciences $20MM Debt Facility

Alimera Sciences, a biopharmaceutical company, announced that its United Kingdom subsidiary, Alimera Sciences Limited, entered into a loan and security agreement with Silicon Valley Bank (SVB) providing for a term loan in the principal amount of $5 million ... [Published ABF Journal - May 09 2013]

Entities: Alimera Sciences Inc, Working Capital, Dan Myers, Iluvien, Alpharetta (United States)

First reported May 08 2013 - Updated May 09 2013 - 2 reports

pSivida launches chronic DME treatment in Germany

pSivida's ILUVIEN, the first sustained release pharmaceutical product for the treatment of chronic diabetic macular edema (DME), is now commercially available in Germany.pSivida's ILUVIEN, the first sustained release pharmaceutical product for the treatment ... [Published Pro Health Service Zone - May 09 2013]

Entities: Diabetic Macular Edema, PSIVIDA CORP, Iluvien

First reported May 08 2013 - Updated May 08 2013 - 3 reports

pSivida Corp reports treatment of first patient with ILUVIEN in Germany following its market launch

Drug delivery products company pSivida Corp (NASDAQ:PSDV) announced on Tuesday the commercial launch of ILUVIEN, the first sustained release pharmaceutical product for the treatment of chronic diabetic macular edema (DME), in Germany.In conjunction with ... [Published Individual.com - May 08 2013]

Entities: Iluvien, PSIVIDA CORP, Germany, Diabetic Macular Edema

First reported May 08 2013 - Updated May 08 2013 - 2 reports

Anthera Announces Additional Data from Phase 2b PEARL-SC; pS. . .

Anthera Announces Additional Data from Phase 2b PEARL-SC; pSivida Announces Commercial Launch of ILUVIENStaff and Wire ReportsBioMed ReportsBelow is a look at some of the headlines for companies that made news in the healthcare sector on May 7, 2013.Anthera ... [Published Equities.com - May 08 2013]

Entities: Systemic Lupus Erythematosus, Iluvien, Anthera Pharmaceuticals Inc, Phase IIb

First reported May 01 2013 - Updated May 02 2013 - 6 reports

Alimera Sciences introduces Iluvien in UK market

pSivida Corp., a specialty pharmaceutical company, has announced that its licensee, Alimera Sciences has introduced Iluvien, the first sustained release pharmaceutical product for the treatment of chronic diabetic macular edema (DME), in the UK for treatment ... [Published PharmaBiz - May 02 2013]

Entities: Iluvien, Alimera Sciences Inc, Diabetic Macular Edema, PSIVIDA CORP

First reported Apr 30 2013 - Updated May 01 2013 - 3 reports

pSivida (PSDV) Receives New PDUFA Date for ILUVIEN

pSivida Corp. (Nasdaq: PSDV) announced that the U.S. Food and Drug Administration (FDA) acknowledged receipt of the resubmission of the New Drug Application (NDA) for ILUVIEN for treatment of chronic diabetic macular edema (DME) and stated that the resubmission ... [Published Street Insider - May 01 2013]

Entities: Iluvien, Diabetic Macular Edema, Prescription Drug User Fee Act, PSIVIDA CORP

First reported Apr 29 2013 - Updated Apr 29 2013 - 5 reports

pSivida launches DME treatment for the privately-insured in UK

Paul Ashton, CEO of pSivida, said it's pleased that Iluvien is now available in the UK for patients who suffer from DME and who have not responded to conventional therapies.The partner of Watertown, Mass.-based pSivida Corp. (Nasdaq:PSDV) has made a treatment ... [Published Boston Business Journal - Apr 29 2013]

Entities: PSIVIDA CORP, Diabetic Macular Edema, Iluvien, United Kingdom

Quotes

Ashton added, "We are also very pleased by Alimera's resubmission of the NDA for ILUVIEN to the FDA and the recently announced PDUFA goal date of October 17, 2013. We will be entitled to 20% of net profits, as defined, in each of Germany and the UK from sales of ILUVIEN by Alimera. If the FDA approves ILUVIEN, we would also be entitled to an additional $25 million milestone payment from Alimera as well as 20% of net profits on any sales in the US by Alimera."

pSivida announces availability of diabetic macular edema drug in Germany [Published Individual.com - May 21 2013]

...therapies," said Albert J Augustin, M D , professor and chairman of the Department of Ophthalmology, Klinikum Karlsruhe, Karlsruhe, Germany. "ILUVIEN brings hope to many patients in Germany affected by this sight-robbing disease."

Alimera Sciences announces availability of DME drug in Germany [Published Individual.com - May 20 2013]

...Paul Ashton, President and CEO of pSivida Corp. "If the FDA approves ILUVIEN, we would be entitled to an additional $25 million milestone payment from Alimera as well as 20 percent of net profits, as defined, on any sales in the U S by Alimera. We are entitled to the same net profit share on sales of ILUVIEN for DME by Alimera in the EU, where Alimera has already launched in the UK and reported plans to launch in Germany in 2013."

pSivida: New ILUVIEN PDUFA Date October 17 [Professional Services Close - Up] [Published Pharmacy Choice - May 14 2013]

...with the implant injection since the product became commercially available," said Dan Myers, Alimera's president and chief executive officer. "This is a significant milestone for not only our Company but also for the patients suffering from the debilitating effects of chronic diabetic macular edema in these regions and their physicians."

Alimera Sciences Reports First Quarter 2013 Financial Results [Published Bio-Medicine - May 10 2013]

More Content

sort by: Date \| Relevance
pSivida announces availability of diabetic macu... [Published Individual.com - May 21 2013]
Alimera Sciences announces availability of DME ... [Published Individual.com - May 20 2013]
InvestorsGuru.com 31 Filtered Mid-Day Market Mo... [Published StockHouse USA - May 20 2013]
Ophthalmology Innovators: Will InSite Follow Re... [Published Seeking Alpha - May 16 2013]
Alimera Sciences Inc is Featured as the Daily M... [Published FinanzNachrichten.de - May 15 2013]
pSivida: New ILUVIEN PDUFA Date October 17 [Pro... [Published Pharmacy Choice - May 14 2013]
pSivida Corp's CEO Discusses Q3 2013 Results - ... [Published Seeking Alpha - May 14 2013]
Healthcare Review: Pharmacyclics, Alimera Scien... [Published BioMedReports - May 13 2013]
Alimera Sciences And Trius Therapeutics: 2 Big ... [Published BioPortfolio - May 13 2013]
Alimera Sciences Management Discusses Q1 2013 R... [Published Seeking Alpha - May 11 2013]
Alimera Sciences Reports First Quarter 2013 Fin... [Published Bio-Medicine - May 10 2013]
Alimera Sciences Reports First Quarter 2013 Fin... [Published Yahoo! Finance - May 09 2013]
Alimera Sciences Reports First Quarter 2013 Fin... [Published ABC News 4 Charleston - May 09 2013]
Alimera Sciences Reports First Quarter 2013 Fin... [Published Individual.com - May 09 2013]
Alimera Sciences signs agreement with Silicon v... [Published Individual.com - May 09 2013]
SVB Provides Alimera Sciences $20MM Debt Facility [Published ABF Journal - May 09 2013]
pSivida launches chronic DME treatment in Germany [Published Pro Health Service Zone - May 09 2013]
Alimera announces availability of diabetic macu... [Published Individual.com - May 08 2013]
pSivida Corp reports treatment of first patient... [Published Individual.com - May 08 2013]
Alimera Sciences Secures $20 Million Debt Facility [Published Bio-Medicine - May 08 2013]
US EQUITIES OPENING HEADLINES INCLUDING: ExxonM... [Published Proactiveinvestors United Kingdom RSS feed - May 08 2013]
Alimera Sciences Secures $20 Million Debt Facility [Published NewsBlaze - May 08 2013]
Alimera Sciences Secures $20 Million Debt Facility [Published KCOY 12 - May 08 2013]
Alimera Sciences Secures $20 Million Debt Facility [Published Barchart - May 08 2013]
pSivida Iluvien available in Germany [Published PBR - News - May 08 2013]
BIOL Does A Deal, BLRX's Lined Up Events, CBST ... [Published RTTNews.com - May 08 2013]
pSivida Corporation achieves commercial launch ... [Published Proactive Investors Australia - May 08 2013]
Anthera Announces Additional Data from Phase 2b... [Published Equities.com - May 08 2013]
Anthera Announces Additional Data from Phase 2b... [Published BioMedReports - May 08 2013]
pSivida Corp. Announces Commercial Launch of IL... [Published EON Business - May 07 2013]

Blogs

sort by: Date \| Relevance
pSivida Iluvien available in Germany [Published PBR - News - May 08 2013] pSivida has announced the availability of the sustained release pharmaceutical product indicated for the treatment of chronic diabetic macular edema (DME), Iluvien, in Germany. ...
NICE do not recommend fluocinolone implant for ... [Published NICE \| National Institute for Health and Clinic ... - Nov 30 2012] In final draft guidance published today (30 November) by the healthcare guidance body, NICE, fluocinolone acetonide intravitreal implant (Iluvien, Alimera Sciences) is not recommended within its marketing authorisation, that is, for the treatment of chronic ...
Pharmacy News [Published Rx Times Pharmacy Magazine - Nov 30 2012] pSivida Corp. Reports Patient Access Scheme Being Developed by Alimera to Address Cost Concerns Following Negative Final Draft Guidance by U.K.’s NICE for ILUVIEN® for DME WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida reports patient access scheme being developed ...

Press Releases

sort by: Date \| Relevance
pSivida Corp. Announces Commercial Launch of IL... [Published EON Business - May 07 2013]
pSivida Corp. Announces Commercial Launch of IL... [Published Business Wire Health News - May 07 2013]
Alimera Sciences Announces First Patient Treate... [Published PR Newswire: Health - May 07 2013]
pSivida Corp. Announces New ILUVIEN® PDUFA Date... [Published EON Business - May 01 2013]
pSivida Corp. Announces New ILUVIEN® PDUFA Date... [Published Business Wire Health News - May 01 2013]